Efficacy Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Patients
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if DiaPep277 can effectively protect the internal
production of insulin in patients newly diagnosed with type 1 diabetes, by stopping the
immune destruction of insulin-producing beta-cells in the pancreas. DiaPep277 acts on the
immune system and is expected to prevent further destruction of the beta-cells by stimulating
regulatory responses, without causing immunological suppression.